TY - JOUR
T1 - Review of immunogenomics and the role of tumor mutational burden as a biomarker for immunotherapy response
AU - Ros, Javier
AU - Baraibar, Iosune
AU - Vivancos, Ana
AU - Rodon, Jordi
N1 - Funding Information:
of Sysmex. Advisory board: Novartis, Merck, Roche, Bristol-Myers Squibb and Guardant Health. Licensing fees: Ferrer (Technology Transfer DX Field). Preclinical research grant: Bristol-Myers Squibb, Novartis, Debio, Sysmex, Cellestia Biotech, Roche and Chittern Jordi Rodon: Research support: Bayer, Novartis Clinical research: Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millenium, GLAXOSMITHKLINE, IPSEN. Advisory board: Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp and Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals Inc., Pfizer, Roche Pharmaceuticals Travel reimbursement: ESMO, Department of Defense, Merck Sharp and Dohme, Louisiana State University, Kelun Pharmaceutical/Klus Pharma, Hunstman Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute, King Abdullah International Medical Research Center. Other: European Journal of Cancer, VHIO/Ministerio De Empleo Y Seguridad Social, Chinese University of Hong Kong, SOLTI, Elsevier, GLAXOSMITHKLINE.
Publisher Copyright:
© 2019 Journal of Immunotherapy and Precision Oncology.
PY - 2019
Y1 - 2019
N2 - Immune checkpoint inhibitors benefit a proportion of patients with cancer, but not all patients nor all histologies will respond to immunotherapy. Therefore, predictive biomarkers are needed. In this review, we outline the ways that lead to hypermutated tumors as well as the potential predictive role of tumor mutational burden (TMB). Findings in selected cancer types suggest that TMB may predict clinical response to immunotherapy, and recently even a prognostic role has been suggested for TMB. An association between high mutational load and clinical benefit was observed in various tumor types; however, it is unclear whether TMB is a strong predictive marker of clinical benefit across all cancers. For that reason, there are still several questions regarding the role of TMB as an immunotherapy biomarker, such as the best measurement technique, the most adequate cutoff, or even whether TMB will be useful for any kind of cancer. We have performed an extensive bibliography research using PubMed with keys words: immunotherapy, tumor mutational load, TMB, immunotherapy biomarkers, and immunotherapy response. In conclusion, TMB has been demonstrated to be a useful biomarker for immunotherapy selection across some cancer types; however, further validation studies are required.
AB - Immune checkpoint inhibitors benefit a proportion of patients with cancer, but not all patients nor all histologies will respond to immunotherapy. Therefore, predictive biomarkers are needed. In this review, we outline the ways that lead to hypermutated tumors as well as the potential predictive role of tumor mutational burden (TMB). Findings in selected cancer types suggest that TMB may predict clinical response to immunotherapy, and recently even a prognostic role has been suggested for TMB. An association between high mutational load and clinical benefit was observed in various tumor types; however, it is unclear whether TMB is a strong predictive marker of clinical benefit across all cancers. For that reason, there are still several questions regarding the role of TMB as an immunotherapy biomarker, such as the best measurement technique, the most adequate cutoff, or even whether TMB will be useful for any kind of cancer. We have performed an extensive bibliography research using PubMed with keys words: immunotherapy, tumor mutational load, TMB, immunotherapy biomarkers, and immunotherapy response. In conclusion, TMB has been demonstrated to be a useful biomarker for immunotherapy selection across some cancer types; however, further validation studies are required.
KW - Cancer
KW - Immunotherapy
KW - Tumor mutational burden
KW - Tumor mutational load
UR - http://www.scopus.com/inward/record.url?scp=85102842163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102842163&partnerID=8YFLogxK
U2 - 10.4103/JIPO.JIPO_19_19
DO - 10.4103/JIPO.JIPO_19_19
M3 - Review article
AN - SCOPUS:85102842163
SN - 2666-2345
VL - 2
SP - 144
EP - 151
JO - Journal of Immunotherapy and Precision Oncology
JF - Journal of Immunotherapy and Precision Oncology
IS - 4
ER -